N-Methyl-azacyclodecan | 6480-47-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Methyl-azacyclodecan
• 英文别名: 1-Methyldecahydroazecine；1-methylazecane
• CAS: 6480-47-3
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: CFDHKUGPXKCLHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Methyl-azacyclodecan 、 碘甲烷 生成 1,1-dimethyl-decahydro-azecinium, iodide
  参考文献：
  名称：

  Prelog; Seiwerth, Chemische Berichte, 1939, vol. 72, p. 1640

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl 5,5’-(methylazanediyl)dipentanoate 在 盐酸 、 potassium tert-butylate 、 一水合肼 、 xylene 、 二乙二醇 作用下， 生成 N-Methyl-azacyclodecan
  参考文献：
  名称：

  Cyclic Aminoacyloins and Aminoketones. IV. Dependence of Transannular Interaction Upon the Relative Location of N and C_CO¹

  摘要：

  DOI：

  10.1021/ja01628a053

文献信息

• [EN] CORTICOSTEROID-BETA-AGONIST-MUSCARINIC ANTAGONIST COMPOUNDS FOR USE IN THERAPY<br/>[FR] COMPOSÉS DE TYPE CORTICOSTÉROÏDE-BÊTA-AGONISTE-ANTAGONISTE MUSCARINIQUE POUR APPLICATIONS THÉRAPEUTIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2011081937A1

  公开（公告）日：2011-07-07

  The instant invention relates to new chemical entities which comprise corticosteroids, phosphorylated β-agonists and muscarinic (M3) antagonists for use in therapy and compositions comprising and processes for preparing the same.

  这项即时发明涉及新的化学实体，包括皮质类固醇、磷酸化β-激动剂和毒蕈碱（M3）拮抗剂，用于治疗以及包含这些化学实体的组合物和制备它们的方法。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'AZAINDOLINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019008011A1

  公开（公告）日：2019-01-10

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及对哺乳动物治疗和/或预防有用的药物，特别是对NF-κB诱导激酶（NIK - 也称为MAP3K14）的抑制剂，用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病，以及自身免疫性疾病。
• GGA DERIVATIVES
  申请人：COYOTE PHARMACEUTICALS, INC.

  公开号：US20150133431A1

  公开（公告）日：2015-05-14

  This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.

  这项发明涉及生育三烯醇丙酮（GGA）衍生物，包括GGA衍生物的药物组合物以及GGA衍生物的用途。